Watch Ticker

PMV Pharmaceuticals, Inc

Go to PMV Pharmaceuticals, Inc Website

$0.00

(%)

Live

Previous Close

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$95.7 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells....

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

PMV Pharmaceuticals, Inc. - PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer

PRINCETON, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that a Phase 1 analysis reported promising anti-tumor activity of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation. Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the TP53 Y220C mutation in solid tumors.

Related tickers: PMVP.

Read Full Article

PMV Pharmaceuticals, Inc. - PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Related tickers: PMVP.

Read Full Article

Trending Tickers

LASE

XNAS

$2.06

(%)

PACW

XNAS

$7.54

(%)

SMFL

XNAS

$3.32

(%)

XNYS

$70.30

(%)

MLGO

XNAS

$0.00

(%)